GRN-related frontotemporal lobar degeneration with Tdp43 inclusions
MONDO:0011842A frontotemporal dementia characterized by variable phenotypic expression typically including social, behavioral, or language deterioration, rather than memory or motor deficits and the presence of TARDBP-positive inclusions that has material basis in mutation in the GRN gene on chromosome 17q21.31.
Also known as: FTLD-TDP, GRN-related, aphasia, primary progressive, dementia, hereditary dysphasic disinhibition, frontotemporal dementia with TDP43 inclusions, GRN-related, frontotemporal dementia, ubiquitin-positive, frontotemporal lobar degeneration with TDP43 inclusions, GRN-related, frontotemporal lobar degeneration with ubiquitin-positive inclusions
51 clinical trials for this condition and its sub-types, 6 tagged with GRN-related frontotemporal lobar degeneration with Tdp43 inclusions itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of GRN-related frontotemporal lobar degeneration with Tdp43 inclusions
-
Progressive non-fluent aphasia 24 trials · 44 incl. sub-types
1 sub-type
- Semantic dementia 32 trials Sub-types →
Most studied deeper sub-types
-
Gene therapy trial targets inherited dementia
Disease control OngoingThis study tests a single-dose gene therapy called LY3884963 in 35 people with frontotemporal dementia caused by GRN gene mutations. The therapy aims to raise levels of a missing protein (progranulin) in the brain. Participants receive the treatment via injection into the fluid a…
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Phase 1/2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC